HomeCompareENDP vs VIG

ENDP vs VIG: Dividend Comparison 2026

ENDP yields 534.19% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ENDP wins by $102783.24M in total portfolio value
10 years
ENDP
ENDP
● Live price
534.19%
Share price
$0.37
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102783.28M
Annual income
$75,120,205,270.55
Full ENDP calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — ENDP vs VIG

📍 ENDP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodENDPVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ENDP + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ENDP pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ENDP
Annual income on $10K today (after 15% tax)
$45,405.98/yr
After 10yr DRIP, annual income (after tax)
$63,852,174,479.97/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, ENDP beats the other by $63,852,174,327.69/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ENDP + VIG for your $10,000?

ENDP: 50%VIG: 50%
100% VIG50/50100% ENDP
Portfolio after 10yr
$51391.65M
Annual income
$37,560,102,724.86/yr
Blended yield
73.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ENDP right now

ENDP
Analyst Ratings
24
Buy
20
Hold
4
Sell
Consensus: Buy
Price Target
$2.00
+434.2% upside vs current
Range: $2.00 — $2.00
VIG
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ENDP buys
0
VIG buys
0
No recent congressional trades found for ENDP or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricENDPVIG
Forward yield534.19%1.64%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$102783.28M$32.4K
Annual income after 10y$75,120,205,270.55$179.15
Total dividends collected$100415.31M$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ENDP vs VIG ($10,000, DRIP)

YearENDP PortfolioENDP Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$64,119$53,418.80$11,304$163.92+$52.8KENDP
2$388,715$320,107.45$12,759$166.33+$376.0KENDP
3$2,229,591$1,813,666.47$14,382$168.52+$2.22MENDP
4$12,107,940$9,722,278.04$16,192$170.52+$12.09MENDP
5$62,298,925$49,343,428.51$18,210$172.34+$62.28MENDP
6$303,936,946$237,277,096.11$20,460$173.98+$303.92MENDP
7$1,407,082,298$1,081,869,766.45$22,968$175.48+$1407.06MENDP
8$6,186,454,865$4,680,876,806.01$25,763$176.83+$6186.43MENDP
9$25,853,337,136$19,233,830,430.18$28,878$178.05+$25853.31MENDP
10$102,783,276,006$75,120,205,270.55$32,350$179.15+$102783.24MENDP

ENDP vs VIG: Complete Analysis 2026

ENDPStock

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Full ENDP Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this ENDP vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ENDP vs SCHDENDP vs JEPIENDP vs OENDP vs KOENDP vs MAINENDP vs DGROENDP vs NOBLENDP vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.